Publication Date
5-1-2023
Journal
Pediatric Hematology and Oncology
DOI
10.1080/08880018.2022.2101722
PMID
35862575
PMCID
PMC10702578
PubMedCentral® Posted Date
5-1-2024
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Humans, Medulloblastoma, Neuroectodermal Tumors, Primitive, Central Nervous System Neoplasms, Survivors, Cerebellar Neoplasms, Epigenesis, Genetic, Epigenetics, aging, survivorship, PNET, medulloblastoma
Abstract
Survivors of childhood central nervous system (CNS) tumors experience early-onset aging-related phenotypes. DNA methylation (DNAm) age is an emerging epigenetic biomarker of physiologic age and may be predictive of chronic health conditions in long-term survivors. This report describes the course of epigenetic age acceleration using post-diagnosis blood samples (median: 3.9 years post-diagnosis; range: 0.04–15.96) from 83 survivors of pediatric CNS tumors. Epigenetic age acceleration was detected in 72% of patients, with an average difference between chronologic and dnam age of 2.58 years (95% Ci: 1.75–3.41, p < 0.001). Time from diagnosis to sample collection correlated with the magnitude of epigenetic age acceleration.
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Biomedical Informatics Commons, Genetics and Genomics Commons, Hematology Commons, Medical Genetics Commons, Medical Molecular Biology Commons, Oncology Commons